论文部分内容阅读
目的:TAnDEM研究在不采取化疗的情况下,比较激素和曲妥珠单抗联合治疗对人类表皮生长因子受体2(HER2)/激素受体双阳性的转移性乳腺癌(MBC)的疗效,TAnDEM为这一领域的第一项随机Ⅲ期临床研究。
OBJECTIVE: The TAnDEM study compared the efficacy of hormone and trastuzumab in the treatment of human epidermal growth factor receptor 2 (HER2) / hormone receptor double positive metastatic breast cancer (MBC) without chemotherapy, TAnDEM is the first randomized phase III clinical study in this area.